Form 10-Q Ultragenyx Pharmaceutica For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Ultragenyx Pharma (RARE) PT Lowered to $66 at Citi
August 5, 2019 6:26 AM EDTCiti analyst Yigal Nochomovitz lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $66.00 (from $69.00) while maintaining a Neutral rating.
... More